These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

141 related articles for article (PubMed ID: 25338999)

  • 21. Discovery of novel natural compound inhibitors targeting estrogen receptor α by an integrated virtual screening strategy.
    Yu E; Xu Y; Shi Y; Yu Q; Liu J; Xu L
    J Mol Model; 2019 Aug; 25(9):278. PubMed ID: 31463793
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Unveiling the ESR1 Conformational Stability and Screening Potent Inhibitors for Breast Cancer Treatment.
    Sharma K; Panwar U; Madhavi M; Joshi I; Chopra I; Soni L; Khan A; Bhrdwaj A; Parihar AS; Mohan VP; Prajapati L; Sharma R; Agrawal S; Hussain T; Nayarisseri A; Singh SK
    Med Chem; 2024; 20(3):352-368. PubMed ID: 37929724
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Pharmacokinetics and drug-likeness of antidiabetic flavonoids: Molecular docking and DFT study.
    Bitew M; Desalegn T; Demissie TB; Belayneh A; Endale M; Eswaramoorthy R
    PLoS One; 2021; 16(12):e0260853. PubMed ID: 34890431
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Identification of DNA Methyltransferase-1 Inhibitor for Breast Cancer Therapy through Computational Fragment-Based Drug Design.
    Alkaff AH; Saragih M; Imana SN; Nasution MAF; Tambunan USF
    Molecules; 2021 Jan; 26(2):. PubMed ID: 33450856
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Protein druggability assessment for natural products using in silico simulation: A case study with estrogen receptor and the flavonoid genistein.
    Ohbuchi K; Hirokawa T
    Gene; 2021 Jul; 791():145726. PubMed ID: 34010704
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prediction and analysis of ligands against estrogen related receptor alpha.
    Chitrala KN; Yeguvapalli S
    Asian Pac J Cancer Prev; 2013; 14(4):2371-5. PubMed ID: 23725143
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Exploring the Synergistic Mechanism of AP2A2 Transcription Factor Inhibition via Molecular Modeling and Simulations as a Novel Computational Approach for Combating Breast Cancer: In Silico Interpretations.
    Niranjan V; Setlur AS; K C; Kumkum S; Dasgupta S; Singh V; Desai V; Kumar J
    Mol Biotechnol; 2024 Sep; 66(9):2497-2521. PubMed ID: 37747672
    [TBL] [Abstract][Full Text] [Related]  

  • 28. DESIGN, SYNTHESIS, MOLECULAR DOCKING AND ANTI-BREAST CANCER ACTIVITY OF NOVEL QUINAZOLINONES TARGETING ESTROGEN RECEPTOR α.
    Ahmed MF; Youns M; Belal A
    Acta Pol Pharm; 2016; 73(1):115-27. PubMed ID: 27008806
    [TBL] [Abstract][Full Text] [Related]  

  • 29. In silico discovery and validation of potent small-molecule inhibitors targeting the activation function 2 site of human oestrogen receptor α.
    Singh K; Munuganti RS; Leblanc E; Lin YL; Leung E; Lallous N; Butler M; Cherkasov A; Rennie PS
    Breast Cancer Res; 2015 Feb; 17(1):27. PubMed ID: 25848700
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Design, synthesis and biological evaluation of novel dual-acting modulators targeting both estrogen receptor α (ERα) and lysine-specific demethylase 1 (LSD1) for treatment of breast cancer.
    He M; Ning W; Hu Z; Huang J; Dong C; Zhou HB
    Eur J Med Chem; 2020 Jun; 195():112281. PubMed ID: 32283297
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Investigation of estrogen receptor (ESR1) for breast cancer from traditional Chinese medicine.
    Hung TC; Lee WY; Chen KB; Chan YC; Chen CY
    Biomed Res Int; 2014; 2014():321486. PubMed ID: 25054138
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Molecular docking and 3D-QSAR-based virtual screening of flavonoids as potential aromatase inhibitors against estrogen-dependent breast cancer.
    Awasthi M; Singh S; Pandey VP; Dwivedi UN
    J Biomol Struct Dyn; 2015; 33(4):804-19. PubMed ID: 24702656
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Coumarin-Fatty Acid Conjugates as Potential ERα/AKT-1 Antagonists for ER Positive Breast Cancer.
    Selvaraj J; John JBA; Joghee NM; Antony J; Wadhwani A; Natarajan J
    Anticancer Agents Med Chem; 2020; 20(4):437-449. PubMed ID: 31746305
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Exploring the novel heterocyclic derivatives as lead molecules for design and development of potent anticancer agents.
    Azad I; Nasibullah M; Khan T; Hassan F; Akhter Y
    J Mol Graph Model; 2018 May; 81():211-228. PubMed ID: 29609141
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Lead Finding from Selected Flavonoids with Antiviral (SARS-CoV-2) Potentials Against COVID-19: An In-silico Evaluation.
    Gorla US; Rao K; Kulandaivelu US; Alavala RR; Panda SP
    Comb Chem High Throughput Screen; 2021; 24(6):879-890. PubMed ID: 32819226
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Synthesis of targeted dibenzo[b,f]thiepines and dibenzo[b,f]oxepines as potential lead molecules with promising anti-breast cancer activity.
    Ansari MI; Hussain MK; Arun A; Chakravarti B; Konwar R; Hajela K
    Eur J Med Chem; 2015 Jun; 99():113-24. PubMed ID: 26067208
    [TBL] [Abstract][Full Text] [Related]  

  • 37. A new class of 1,3,5-triazine-based selective estrogen receptor degraders (SERDs): Lead optimization, molecular docking and dynamic simulation.
    Lu X; Huang A; Xiao M; Sun L; Mao J; Luo G; Xiang H
    Bioorg Chem; 2020 Apr; 97():103666. PubMed ID: 32088420
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Design, Synthesis, and Biological Evaluation of 2-(2-Bromo-3-nitrophenyl)-5-phenyl-1,3,4-oxadiazole Derivatives as Possible Anti-Breast Cancer Agents.
    Ananth AH; Manikandan N; Rajan RK; Elancheran R; Lakshmithendral K; Ramanathan M; Bhattacharjee A; Kabilan S
    Chem Biodivers; 2020 Feb; 17(2):e1900659. PubMed ID: 31995280
    [TBL] [Abstract][Full Text] [Related]  

  • 39.
    Sharma R; Jaitak V
    Nat Prod Res; 2020 Jun; 34(11):1571-1574. PubMed ID: 30580607
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Fragment-based in silico modeling of multi-target inhibitors against breast cancer-related proteins.
    Speck-Planche A; Cordeiro MNDS
    Mol Divers; 2017 Aug; 21(3):511-523. PubMed ID: 28194627
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.